Sign in
Active, not recruitingPhase 4

Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage

Key facts

Who runs it
Clinical Center of Vojvodina
Where
Serbia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
60 people enrolled
Started
25 Jun 2025
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • stromal vascular fraction (SVF)
  • CP
Record updated
12 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Adults (≥18 years)
  • Radiologically confirmed knee OA (grades II-IV, Kellgren-Lawrence scale)
  • KOOS pain score ≤ 60 points
  • Symptomatic degenerative knee disease with at least 6 months of persistent pain
  • No history of major knee trauma or prolonged immobilization (>10 days)

Who cannot take part

  • Current anticoagulant or antiplatelet therapy
  • Intra-articular corticosteroid injection within the past 6 months
  • History of major knee trauma or surgery
  • Minors (<18 years)
  • Asymptomatic OA (KL grade 0-I)
  • Severe axial deformity (varus >10°, valgus >10°)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized, controlled clinical trial will evaluate the safety and effectiveness of autologous adipose-derived stromal vascular fraction (SVF) therapy in patients with knee osteoarthritis (OA) grades II-IV, compared with standard chondroprotective (CP) treatment. The study will enroll male and female patients and follow them for 12 months, assessing pain (VAS), function (WOMAC, KOOS, SF-36), radiologic progression, and safety (adverse events). The trial aims to determine whether SVF therapy provides superior clinical outcomes and to inform evidence-based recommendations for OA management in the Serbian population.

The 2 groups in the trial

  • SVF groupTreatment being tested

    In this arm, we included patients which will be treated with intraarticular injection of SVF from fat pad

    Treatment: stromal vascular fraction (SVF)

  • CP groupExisting treatment, for comparison

    In this arm we will included patient swhich will be treated with Reviscon Re cross HA injection by MV Pharm

    Treatment: CP

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
12 February 2026